Kumar P P, Patil A A, Syh H W, Chu W K, Reeves M A
Division of Radiation Oncology, University of Nebraska, Medical Center, Omaha.
Cancer. 1993 Jun 1;71(11):3726-31. doi: 10.1002/1097-0142(19930601)71:11<3726::aid-cncr2820711141>3.0.co;2-h.
The treatment of primary and recurrent skull base meningiomas presents a formidable surgical problem.
Fifteen patients with primary and recurrent skull base meningiomas were treated by means of interstitial irradiation with iodine 125 (125I) seed implantation. The physical characteristics of 125I enabled the authors to administer a minimum tumor dose ranging from 100 to 500 Gy at a low dose rate of 0.05-0.25 Gy per hour.
All 15 patients are alive at a median follow-up of 29 months. Of the 15 patients, 2 with calcification and 2 without calcification achieved only partial responses. The remaining 11 patients achieved a complete response. No early or late complications were observed.
From these data, the authors conclude that interstitial irradiation with 125I seeds is an effective, safe, and simple method in the treatment of both recurrent and primary skull base meningiomas.
原发性和复发性颅底脑膜瘤的治疗是一个棘手的外科问题。
15例原发性和复发性颅底脑膜瘤患者接受了碘125（125I）粒子植入间质内照射治疗。125I的物理特性使作者能够以每小时0.05 - 0.25 Gy的低剂量率给予100至500 Gy的最小肿瘤剂量。
15例患者均存活，中位随访时间为29个月。15例患者中，2例有钙化和2例无钙化的患者仅获得部分缓解。其余11例患者获得完全缓解。未观察到早期或晚期并发症。
根据这些数据，作者得出结论，125I粒子间质内照射是治疗复发性和原发性颅底脑膜瘤的一种有效、安全且简单的方法。
